Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450372 · ClinicalTrials.gov registry record · Phase 2
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00450372 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 38 participants.
The verdict
NCT00450372, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating patients with metastatic melanoma that cannot be removed by surgery.
Interventions
- BIOLOGICAL ADI-PEG-20
- OTHER Pharmacology Studies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2004-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450372
The ClinicalTrials.gov registry entry for NCT00450372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADI-PEG-20 is the first listed.
NCT00450372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450372 about?
NCT00450372 is a clinical study titled "Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery". RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating patients with metastatic melanoma that cannot be removed by surgery.
What is the current status of trial NCT00450372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2004-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00450372?
The interventions under investigation include: ADI-PEG-20 (BIOLOGICAL), Pharmacology Studies (OTHER).
Who is sponsoring clinical trial NCT00450372?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.